Literature DB >> 6488504

Vasodilative effect of hydralazine in awake dogs: the roles of prostaglandins and the sympathetic nervous system.

K Maekawa, C S Liang, A Tsui, B T Chen, S Kawashima.   

Abstract

The relative roles of prostaglandins and the sympathetic nervous system in mediating the hypotensive effects of hydralazine were studied in awake dogs with and without pretreatment with indomethacin, propranolol, and phentolamine. In normal dogs, mean aortic pressure decreased 23 +/- 4 mm Hg after administration of hydralazine (cumulative dose of 0.8 mg/kg). This hypotensive effect of hydralazine was potentiated by phentolamine but was abolished by propranolol. Indomethacin caused a paradoxic pressor response (11 +/- 3 mm Hg) to hydralazine, which also was abolished by addition of phentolamine. Hydralazine produced vasodilation in the coronary, skeletal muscle (quadriceps), splanchnic, and renal circulations in normal dogs. The increase in coronary blood flow was associated with increased cardiac oxygen consumption and narrowed arteriovenous oxygen difference across the heart. Propranolol reduced the increases in cardiac oxygen consumption and coronary blood flow, but only indomethacin abolished the narrowed arteriovenous oxygen difference, suggesting that the increase in coronary blood flow was related to both the increased cardiac oxygen demand and prostaglandin-mediated active coronary vasodilation. The decrease in skeletal muscle vascular resistance after hydralazine was abolished by propranolol. Skeletal muscle vascular resistance actually increased after administration of hydralazine in dogs pretreated with both propranolol and indomethacin. These effects were blocked by the addition of phentolamine. Unlike the normal response, renal and splanchnic vascular resistances increased after administration of hydralazine in dogs pretreated with indomethacin. The splanchnic vasoconstriction was abolished by phentolamine, but the renal vascular change was affected by neither phentolamine nor propranolol. The results indicate that hydralazine does not produce uniform vasodilation in all organs and that the cardiovascular actions of hydralazine involve both prostaglandins and the sympathetic nervous system.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6488504     DOI: 10.1161/01.cir.70.5.908

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

1.  The interaction of hydralazine with a semicarbazide-sensitive amine oxidase in brown adipose tissue of the rat. Its use as a radioactive ligand for the enzyme.

Authors:  M A Barrand; B A Callingham
Journal:  Biochem J       Date:  1985-12-01       Impact factor: 3.857

Review 2.  Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations.

Authors:  W J Remme
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 3.  Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure.

Authors:  J P Mulrow; M H Crawford
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

4.  Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction.

Authors:  Payman Zamani; Scott Akers; Haideliza Soto-Calderon; Melissa Beraun; Maheswara R Koppula; Swapna Varakantam; Deepa Rawat; Prithvi Shiva-Kumar; Philip G Haines; Jesse Chittams; Raymond R Townsend; Walter R Witschey; Patrick Segers; Julio A Chirinos
Journal:  J Am Heart Assoc       Date:  2017-02-20       Impact factor: 5.501

5.  The potential for prazosin and calcitonin gene-related peptide (CGRP) in causing hypoxia in tumours.

Authors:  I A Burney; R J Maxwell; J R Griffiths; S B Field
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.